EU supplementary protection certificates: beyond the CJEU
This article was originally published in SRA
Katie McConnell argues that recent decisions by the English courts on SPCs prove that last year's CJEU judgments fail to provide certainty for the pharmaceutical industry and provide a basis for yet more litigation.
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.